Proposed Model of ponatinib-mediated disruption of intratumoral Src/Lyn or /Fyn heterodimers. (IMAGE)

Science China Press

Proposed Model of ponatinib-mediated disruption of intratumoral Src/Lyn or /Fyn heterodimers.

Caption

Ponatinib disrupts the interaction between intratumoral Src with Lyn or Fyn to inhibit the phosphorylation of these two SFKs, and resultantly inhibits tumor malignancy. However, Src cannot interact with Lyn or Fyn in normal cells.

Credit

©Science China Press

Usage Restrictions

Use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.